UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000003570 |
|---|---|
| Receipt number | R000004273 |
| Scientific Title | A phase II study of metronomic paclitaxel + cyclophosphamide + capecitabine (PCX) followed by 5-fluorouracil + epirubicin + cyclophosphamide (FEC) as preoperative chemotherapy for triple negative or low hormone receptors/HER2 negative primary breast cancer (JBCRG-13) |
| Date of disclosure of the study information | 2010/05/10 |
| Last modified on | 2021/08/18 10:23:10 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2010/05/06 12:04:37 | ||
| 2 | Update | 2011/08/29 15:02:05 | Recruitment status |
|
| 3 | Update | 2013/12/06 10:00:52 | Division name Division name Division name Division name Post marketing survey by drug manufacture etc., specified by Japanese law. Institutions |
|
| 4 | Update | 2014/12/10 11:25:11 | Address Address TEL Address1 Tel1 |
|
| 5 | Update | 2015/12/17 10:42:43 | Publication of results |
|
| 6 | Update | 2016/07/08 15:20:47 | Name of primary person or sponsor Organization Organization Division Category of Funding Organization |
|
| 7 | Update | 2017/05/10 11:30:16 | Recruitment status Anticipated trial start date Last follow-up date |
|
| 8 | Update | 2017/05/10 11:33:40 | Organization Division Category of Funding Organization |
|
| 9 | Update | 2018/08/24 10:04:52 | UMIN ID1 |
|
| 10 | Update | 2021/08/18 10:23:10 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
